vs
Side-by-side financial comparison of CAMDEN NATIONAL CORP (CAC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
CAMDEN NATIONAL CORP is the larger business by last-quarter revenue ($64.3M vs $37.2M, roughly 1.7× Organogenesis Holdings Inc.). Over the past eight quarters, CAMDEN NATIONAL CORP's revenue compounded faster (22.6% CAGR vs -46.5%).
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
CAC vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $64.3M | $37.2M |
| Net Profit | $21.9M | — |
| Gross Margin | — | 30.8% |
| Operating Margin | — | -185.1% |
| Net Margin | 34.0% | — |
| Revenue YoY | — | -57.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.29 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $64.3M | $37.2M | ||
| Q4 25 | $68.1M | $225.6M | ||
| Q3 25 | $65.4M | $150.9M | ||
| Q2 25 | $62.3M | $101.0M | ||
| Q1 25 | $60.1M | $86.7M | ||
| Q4 24 | $47.6M | $126.7M | ||
| Q3 24 | $45.0M | $115.2M | ||
| Q2 24 | $42.8M | $130.2M |
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | $43.7M | ||
| Q3 25 | $21.2M | $21.6M | ||
| Q2 25 | $14.1M | $-9.4M | ||
| Q1 25 | $7.3M | $-18.8M | ||
| Q4 24 | $14.7M | $7.7M | ||
| Q3 24 | $13.1M | $12.3M | ||
| Q2 24 | $12.0M | $-17.0M |
| Q1 26 | — | 30.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 72.6% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 76.7% | ||
| Q2 24 | — | 77.6% |
| Q1 26 | — | -185.1% | ||
| Q4 25 | 41.5% | 28.1% | ||
| Q3 25 | 40.5% | 13.7% | ||
| Q2 25 | 28.5% | -12.5% | ||
| Q1 25 | 10.3% | -30.9% | ||
| Q4 24 | 38.7% | 8.1% | ||
| Q3 24 | 35.2% | 5.4% | ||
| Q2 24 | 34.7% | -10.7% |
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | 19.4% | ||
| Q3 25 | 32.4% | 14.3% | ||
| Q2 25 | 22.6% | -9.3% | ||
| Q1 25 | 12.2% | -21.7% | ||
| Q4 24 | 30.8% | 6.1% | ||
| Q3 24 | 29.1% | 10.7% | ||
| Q2 24 | 28.0% | -13.1% |
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | $0.31 | ||
| Q3 25 | $1.25 | $0.11 | ||
| Q2 25 | $0.83 | $-0.10 | ||
| Q1 25 | $0.43 | $-0.17 | ||
| Q4 24 | $1.00 | $0.05 | ||
| Q3 24 | $0.90 | $0.09 | ||
| Q2 24 | $0.81 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $91.4M |
| Total DebtLower is stronger | $514.4M | — |
| Stockholders' EquityBook value | $710.0M | — |
| Total Assets | $7.0B | $520.0M |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $91.4M | ||
| Q4 25 | — | $93.7M | ||
| Q3 25 | — | $63.7M | ||
| Q2 25 | — | $73.1M | ||
| Q1 25 | — | $110.0M | ||
| Q4 24 | — | $135.6M | ||
| Q3 24 | — | $94.3M | ||
| Q2 24 | — | $89.9M |
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $63.8M |
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $300.1M | ||
| Q3 25 | $676.4M | $255.1M | ||
| Q2 25 | $652.1M | $233.2M | ||
| Q1 25 | $640.1M | $242.9M | ||
| Q4 24 | $531.2M | $262.9M | ||
| Q3 24 | $529.9M | $278.5M | ||
| Q2 24 | $508.3M | $263.5M |
| Q1 26 | $7.0B | $520.0M | ||
| Q4 25 | $7.0B | $598.7M | ||
| Q3 25 | $7.0B | $509.8M | ||
| Q2 25 | $6.9B | $461.1M | ||
| Q1 25 | $7.0B | $467.4M | ||
| Q4 24 | $5.8B | $497.9M | ||
| Q3 24 | $5.7B | $446.3M | ||
| Q2 24 | $5.7B | $443.2M |
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
ORGO
Segment breakdown not available.
